Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes

References

• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med. 1993 Sep 30;329(14):977–986.
   PubMed Web of Science ®Google Scholar
• Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr. 1994 Aug;125(2):177–188.
   PubMed Web of Science ®Google Scholar
• Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care. 2015 Jun;38(6):971–978.
   PubMed Web of Science ®Google Scholar
• American Diabetes A. 5. Glycemic targets. Diabetes Care. 2016 Jan;39(Suppl 1):S39–46.
   PubMedGoogle Scholar
• ADA. Children and adolescents. Sec. 11 in standards of medical care in diabetes. Diabetes Care. 2016;39(Supplement 1):S86–S93.
   PubMedGoogle Scholar
• Campbell MS, Schatz DA, Chen V, et al. A contrast between children and adolescents with excellent and poor control: the T1D exchange clinic registry experience. Pediatric Diabetes. 2014 Mar;15(2):110–117.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Zinman B, Cleary PA, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009 Jul 27;169(14):1307–1316.
   PubMedGoogle Scholar
• Dinneen S, Alzaid A, Turk D, et al. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia. 1995 Mar;38(3):337–343.
   PubMed Web of Science ®Google Scholar
• Greenbaum CJ, Prigeon RL, D’Alessio DA. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. Diabetes. 2002 Apr;51(4):951–957.
   PubMed Web of Science ®Google Scholar
• Sherr J, Tsalikian E, Fox L, et al. Dysregulation of alpha-cell function in youth during the first 2 years of T1D: recipricol abnormalities in glucagon responses to mixed meal feedings and hypoglycemia. Diabetes. 2012;61(Supplement 1):A52–A53.
   Google Scholar
• Heinemann L. The failure of exubera: are we beating a dead horse? J Diabetes Sci Technol. 2008 May;2(3):518–529.
   PubMedGoogle Scholar
• Steiner S, Pfutzner A, Wilson BR, et al. Technosphere/Insulin–proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes. 2002 Jan;110(1):17–21.
   PubMed Web of Science ®Google Scholar
• Baughman RA, Amin N, Watkins E, et al. A phase 1, open-label, randomized dose proportionality study of Technosphere Insulin Inhalation Powder (TI) doses up to 80 U administered with the Gen2 inhaler in healthy subjects. Diabetes. 2013;62(supplement 1):A251abstract 982–P.
   Google Scholar
• Bode BW, McGill JB, Lorber DL, et al. Inhaled technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015 Dec;38(12):2266–2273.
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Mann AE, Steiner SS. Technosphere/Insulin–a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther. 2002;4(5):589–594.
   PubMedGoogle Scholar
• Afrezza package insert. cited 2016 Dec; Available from: http://hcp.afrezza.com/afrezza.pdf
   Google Scholar
• Pfutzner A, Forst T. Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug Deliv. 2005 Nov;2(6):1097–1106.
   PubMedGoogle Scholar
• Garg SK, Kelly WC, Freson BJ, et al. Treat to target technosphere insulin in patients with type 1 diabetes. In: American diabetes association 71st scientific sessions. San Diego (CA); 2011.
   Google Scholar
• Fineberg SE, Kawabata TT, Krasner AS, et al. Insulin antibodies with pulmonary delivery of insulin. Diabetes Technol Ther. 2007 Jun;9(Suppl 1):S102–10.
   PubMed Web of Science ®Google Scholar
• Pittas AG, Westcott GP, Balk EM. Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015 Nov;3(11):886–894.
   PubMed Web of Science ®Google Scholar
• Koda JE, Fineman M, Rink TJ, et al. Amylin concentrations and glucose control. Lancet. 1992 May 9;339(8802):1179–1180.
   PubMed Web of Science ®Google Scholar
• Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002 Apr;25(4):724–730.
   PubMed Web of Science ®Google Scholar
• Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004 Nov;21(11):1204–1212.
   PubMed Web of Science ®Google Scholar
• Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 Oct;29(10):2189–2195.
   PubMed Web of Science ®Google Scholar
• Hassan K, Heptulla RA. Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus. Pediatric Diabetes. 2009 Jun;10(4):264–268.
   PubMed Web of Science ®Google Scholar
• Hinshaw L, Schiavon M, Dadlani V, et al. Effect of pramlintide on postprandial glucose fluxes in type 1 diabetes. J Clin Endocrinol Metab. 2016 May;101(5):1954–1962.
   PubMed Web of Science ®Google Scholar
• Muller WA, Faloona GR, Aguilar-Parada E, et al. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med. 1970 Jul 16;283(3):109–115.
   PubMed Web of Science ®Google Scholar
• Marrero DG, Crean J, Zhang B, et al. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 2007 Feb;30(2):210–216.
   PubMed Web of Science ®Google Scholar
• Vella S, Buetow L, Royle P, et al. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010 May;53(5):809–820.
   PubMed Web of Science ®Google Scholar
• Lund SS, Tarnow L, Astrup AS, et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One. 2008;3(10):e3363.
   PubMed Web of Science ®Google Scholar
• Libman IM, Miller KM, DiMeglio LA, et al. A randomized trial of metformin as an adjunct therapy for overweight/obese adolescents with type 1 diabetes. JAMA. Forthcoming 2015.
   PubMed Web of Science ®Google Scholar
• Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs. 1999;58(Suppl 1):31-9; discussion 75-82.
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409–1439.
   PubMed Web of Science ®Google Scholar
• Theodorakis MJ, Carlson O, Michopoulos S, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am Physiol Endocrinol Metab. 2006 Mar;290(3):E550–9.
   PubMed Web of Science ®Google Scholar
• Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function. Diabetes. 2011 May;60(5):1599–1607.
   PubMed Web of Science ®Google Scholar
• Kjems LL, Holst JJ, Volund A, et al. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003 Feb;52(2):380–386.
   PubMed Web of Science ®Google Scholar
• Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992 May 14;326(20):1316–1322.
   PubMed Web of Science ®Google Scholar
• Holst JJ. Incretin hormones and the satiation signal. Int J Obes (Lond). 2013 Sep;37(9):1161–1168.
   PubMed Web of Science ®Google Scholar
• Kuhadiya ND, Malik R, Bellini NJ, et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocrine Practice. 2013 Nov-Dec;19(6):963–967.
   PubMed Web of Science ®Google Scholar
• Harrison LB, Mora PF, Clark GO, et al. Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. J Investig Med. 2013 Jan;61(1):40–44.
   PubMed Web of Science ®Google Scholar
• Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol. 2011 Jul;165(1):77–84.
   PubMed Web of Science ®Google Scholar
• Kuhadiya ND, Dhindsa S, Ghanim H, et al. Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks. Diabetes Care. 2016 Jun;39(6):1027–1035.
   PubMed Web of Science ®Google Scholar
• Kielgast U, Krarup T, Holst JJ, et al. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care. 2011 Jul;34(7):1463–1468.
   PubMed Web of Science ®Google Scholar
• Frandsen CS, Dejgaard TF, Holst JJ, et al. Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blinded parallel study. Diabetes Care. 2015 Oct 20;38:2250–2257.
   PubMed Web of Science ®Google Scholar
• Dejgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016 Mar;4(3):221–232.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016 Oct;39(10):1702–1710.
   PubMed Web of Science ®Google Scholar
• Ahren B, Hirsch IB, Pieber TR, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care. 2016 Oct;39(10):1693–1701.
   PubMed Web of Science ®Google Scholar
• Traina AN, Lull ME, Hui AC, et al. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes. 2014 Aug;38(4):269–272.
   PubMed Web of Science ®Google Scholar
• Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care. 2009 Dec;32(12):2251–2257.
   PubMed Web of Science ®Google Scholar
• Kelly AS, Rudser KD, Nathan BM, et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr. 2013 Apr;167(4):355–360.
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003 Jun;88(6):2706–2713.
   PubMed Web of Science ®Google Scholar
• Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015 May 23;385(9982):2057–2066.
   PubMed Web of Science ®Google Scholar
• Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010 Jun;33(6):1255–1261.
   PubMed Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011 May;96(5):1301–1310.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 2013 Oct;62(10):3316–3323.
   PubMed Web of Science ®Google Scholar
• Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017 May;5(5):341–354.
   PubMed Web of Science ®Google Scholar
• Kapitza C, Dahl K, Jacobsen JB, et al. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017 May 19;60:1390–1399.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2015 Sep 10:dc150165.
   Web of Science ®Google Scholar
• Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017 Apr;5(4):251–260.
   PubMed Web of Science ®Google Scholar
• Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care. 2013 Jul;36(7):2126–2132.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006 Nov 11;368(9548):1696–1705.
   PubMed Web of Science ®Google Scholar
• Ellis SL, Moser EG, Snell-Bergeon JK, et al. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med. 2011 Oct;28(10):1176–1181.
   PubMed Web of Science ®Google Scholar
• Garg SK, Moser EG, Bode BW, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocrine Practice. 2013 Jan-Feb;19(1):19–28.
   PubMed Web of Science ®Google Scholar
• Griffin KJ, Thompson PA, Gottschalk M, et al. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2014 Sep;2(9):710–718.
   PubMed Web of Science ®Google Scholar
• Foley JE, Ligueros-Saylan M, He YL, et al. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res. 2008 Oct;40(10):727–730.
   PubMed Web of Science ®Google Scholar
• Farngren J, Persson M, Schweizer A, et al. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab. 2012 Oct;97(10):3799–3806.
   PubMed Web of Science ®Google Scholar
• Craddy P, Palin HJ, Johnson KI. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther. 2014 Jun;5(1):1–41.
   PubMed Web of Science ®Google Scholar
• Suarez-Pinzon WL, Power RF, Yan Y, et al. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes. 2008 Dec;57(12):3281–3288.
   PubMed Web of Science ®Google Scholar
• Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013 Oct;1(2):140–151.
   PubMed Web of Science ®Google Scholar
• Tahrani AA, Bailey CJ, Del Prato S, et al. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011 Jul 9;378(9786):182–197.
   PubMed Web of Science ®Google Scholar
• Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014 Mar 4.
   Web of Science ®Google Scholar
• Tamez HE, Tamez AL, Garza LA, et al. Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. J Diabetes Metab Disord. 2015;14:78.
   PubMed Web of Science ®Google Scholar
• Henry RR, Thakkar P, Tong C, et al. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015 Dec;38(12):2258–2265.
   PubMed Web of Science ®Google Scholar
• Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015 Jul;38(7):1181–1188.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012 Aug;8(8):495–502.
   PubMed Web of Science ®Google Scholar
• Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011 Mar;60(3):890–898.
   PubMed Web of Science ®Google Scholar
• Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015 Oct;17(10):928–935.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Peters AL, Slee A, et al. The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care. 2017 Feb;40(2):171–180.
   PubMed Web of Science ®Google Scholar
• Administration UFaD. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015 cited 2015 Jun 19; Available from: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm
   Google Scholar
• Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Jun 15;38:1687–1693.
   PubMed Web of Science ®Google Scholar
• Steil GM, Rebrin K, Darwin C, et al. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes. 2006 Dec;55(12):3344–3350.
   PubMed Web of Science ®Google Scholar
• Weinzimer SA, Steil GM, Swan KL, et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008 May;31(5):934–939.
   PubMed Web of Science ®Google Scholar
• Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010 Feb 27;375(9716):743–751.
   PubMed Web of Science ®Google Scholar
• Hovorka R, Elleri D, Thabit H, et al. Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care. 2014 May;37(5):1204–1211.
   PubMed Web of Science ®Google Scholar
• Murphy HR, Elleri D, Allen JM, et al. Closed-loop insulin delivery during pregnancy complicated by type 1 diabetes. Diabetes Care. 2011 Feb;34(2):406–411.
   PubMed Web of Science ®Google Scholar
• Murphy HR, Kumareswaran K, Elleri D, et al. Safety and efficacy of 24-h closed-loop insulin delivery in well-controlled pregnant women with type 1 diabetes: a randomized crossover case series. Diabetes Care. 2011 Dec;34(12):2527–2529.
   PubMed Web of Science ®Google Scholar
• Kovatchev B, Cobelli C, Renard E, et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol. 2010 Nov;4(6):1374–1381.
   PubMedGoogle Scholar
• Nimri R, Danne T, Kordonouri O, et al. The “Glucositter” overnight automated closed loop system for type 1 diabetes: a randomized crossover trial. Pediatric Diabetes. 2013 May;14(3):159–167.
   PubMed Web of Science ®Google Scholar
• Anderson SM, Raghinaru D, Pinsker JE, et al. Multinational home use of closed-loop control is safe and effective. Diabetes Care. 2016 Jul;39(7):1143–1150.
   PubMed Web of Science ®Google Scholar
• Nimri R, Muller I, Atlas E, et al. MD-logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care. 2014 Nov;37(11):3025–3032.
   PubMed Web of Science ®Google Scholar
• Kovatchev B, Cheng P, Anderson SM, et al. Feasibility of long-term closed-loop control: a multicenter 6-month trial of 24/7 automated insulin delivery. Diabetes Technol Ther. 2017 Jan;19(1):18–24.
   PubMed Web of Science ®Google Scholar
• El-Khatib FH, Balliro C, Hillard MA, et al. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2017 Jan 28;389(10067):369–380.
   PubMed Web of Science ®Google Scholar
• Kovatchev BP, Renard E, Cobelli C, et al. Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. Diabetes Care. 2013 Jul;36(7):1851–1858.
   PubMed Web of Science ®Google Scholar
• Del Favero S, Bruttomesso D, Di Palma F, et al. First use of model predictive control in outpatient wearable artificial pancreas. Diabetes Care. 2014;37(5):1212–1215.
   PubMed Web of Science ®Google Scholar
• Barnard KD, Wysocki T, Allen JM, et al. Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents. BMJ Open Diabetes Res Care. 2014;2(1):e000025.
   PubMedGoogle Scholar
• Thabit H, Elleri D, Leelarathna L, et al. Unsupervised overnight closed loop insulin delivery during free living: analysis of randomised cross-over home studies in adults and adolescents with type 1 diabetes. Lancet. 2015 Feb 26;385(Suppl 1):S96.
   PubMedGoogle Scholar
• Thabit H, Elleri D, Leelarathna L, et al. Unsupervised home use of overnight closed-loop system over 3 to 4 weeks - pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. Diabetes Obes Metab. 2014 Dec 10;17(5):452–458.
   Google Scholar
• Thabit H, Lubina-Solomon A, Stadler M, et al. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol. 2014 Sep;2(9):701–709.
   PubMed Web of Science ®Google Scholar
• Thabit H, Tauschmann M, Allen JM, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med. 2015 Sep 17;373:2129–2140.
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016 Oct 4;316(13):1407–1408.
   PubMed Web of Science ®Google Scholar
• Garg SK, Weinzimer SA, Tamborlane WV, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017 Jan 30;19:155–163.
   PubMed Web of Science ®Google Scholar
• Ly TT, Breton MD, Keith-Hynes P, et al. Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp. Diabetes Care. 2014 Aug;37(8):2310–2316.
   PubMed Web of Science ®Google Scholar
• Ly TT, Buckingham BA, DeSalvo DJ, et al. Day-and-night closed-loop control using the unified safety system in adolescents with type 1 diabetes at camp. Diabetes Care. 2016 Jun 6;39:e106-e107.
   PubMed Web of Science ®Google Scholar
• Ly TT, Keenan DB, Roy A, et al. Automated overnight closed-loop control using a proportional-integral-derivative algorithm with insulin feedback in children and adolescents with type 1 diabetes at diabetes camp. Diabetes Technol Ther. 2016 Jun;18(6):377–384.
   PubMed Web of Science ®Google Scholar
• Ly TT, Roy A, Grosman B, et al. Day and night closed-loop control using the integrated medtronic hybrid closed-loop system in type 1 diabetes at diabetes camp. Diabetes Care. 2015 Jul;38(7):1205–1211.
   PubMed Web of Science ®Google Scholar
• Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014 Jul 24;371(4):313–325.
   PubMed Web of Science ®Google Scholar
• Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013 Feb 28;368(9):824–833.
   PubMed Web of Science ®Google Scholar
• Del Favero S, Boscari F, Messori M, et al. Randomized summer camp crossover trial in 5- to 9-year-old children: outpatient wearable artificial pancreas is feasible and safe. Diabetes Care. 2016 Jul;39(7):1180–1185.
   PubMed Web of Science ®Google Scholar
• Abraham MB, Nicholas JA, Ly TT, et al. Safety and efficacy of the predictive low glucose management system in the prevention of hypoglycaemia: protocol for randomised controlled home trial to evaluate the Suspend before low function. BMJ Open. 2016 Apr 15;6(4):e011589.
   PubMed Web of Science ®Google Scholar
• Weissberg-Benchell J, Hessler D, Polonsky WH, et al. Psychosocial impact of the bionic pancreas during summer camp. J Diabetes Sci Technol. 2016 Jul;10(4):840–844.
   PubMedGoogle Scholar
• Troncone A, Bonfanti R, Iafusco D, et al. Evaluating the experience of children with type 1 diabetes and their parents taking part in an artificial pancreas clinical trial over multiple days in a diabetes camp setting. Diabetes Care. 2016 Dec;39(12):2158–2164.
   PubMed Web of Science ®Google Scholar
• Barnard KD, Wysocki T, Thabit H, et al. Psychosocial aspects of closed- and open-loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting. Diabet Med. 2015 May;32(5):601–608.
   PubMed Web of Science ®Google Scholar
• Barnard KD, Wysocki T, Ully V, et al. Closing the Loop in adults, children and adolescents with suboptimally controlled type 1 diabetes under free living conditions: a psychosocial substudy. J Diabetes Sci Technol. 2017 Apr 1:1932296817702656.
   Google Scholar
• Iturralde E, Tanenbaum ML, Hanes SJ, et al. Expectations and attitudes of individuals with type 1 diabetes after using a hybrid closed loop system. Diabetes Educ. 2017 Apr;43(2):223–232.
   PubMed Web of Science ®Google Scholar
• Russell SJ, El-Khatib FH, Nathan DM, et al. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care. 2012 Nov;35(11):2148–2155.
   PubMed Web of Science ®Google Scholar
• Castle JR, Engle JM, El Youssef J, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care. 2010 Jun;33(6):1282–1287.
   PubMed Web of Science ®Google Scholar
• Haidar A, Legault L, Dallaire M, et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ. 2013 Mar 5;185(4):297–305.
   PubMed Web of Science ®Google Scholar
• Van Bon AC, Jonker LD, Koebrugge R, et al. Feasibility of a bihormonal closed-loop system to control postexercise and postprandial glucose excursions. J Diabetes Sci Technol. 2012 Sep;6(5):1114–1122.
   PubMedGoogle Scholar
• Pedersen JS. The nature of amyloid-like glucagon fibrils. J Diabetes Sci Technol. 2010 Nov;4(6):1357–1367.
   PubMedGoogle Scholar
• NovoNordisk. GlucaGen prescribing information. 2014 cited 2014 Aug 4. Available from: http://www.novonordiskmedicalinformation.com//file_upload/GlucaGenHypoKit Prescribing Information,April2014.pdf
   Google Scholar
• Lily. Glucagon for Injection prescribing information. 2015. [cited 2017 May 3]. Available from: http://pi.lilly.com/us/rglucagon-pi.pdf
   Google Scholar
• Jackson MA, Caputo N, Castle JR, et al. Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas. Curr Diab Rep. 2012 Dec;12(6):705–710.
   PubMed Web of Science ®Google Scholar
• Steiner SS, Li M, Hauser R, et al. Stabilized glucagon formulation for bihormonal pump use. J Diabetes Sci Technol. 2010 Nov;4(6):1332–1337.
   PubMedGoogle Scholar
• Bakhtiani PA, Caputo N, Castle JR, et al. A novel, stable, aqueous glucagon formulation using ferulic acid as an excipient. J Diabetes Sci Technol. 2015 Jan;9(1):17–23.
   PubMedGoogle Scholar
• Cersosimo E, Cummins MJ, Kinzell J, et al. A phase 2 comparitive safety pk/pd study of stable nonaqueous glucagon (G-Pen) vs. lilly glucagon for treatment of severe hypoglycemia. In: American diabetes association 74th scientific session. San Francisco (CA); 2014.
   Google Scholar
• Newswanger B, Ammons S, Phadnis N, et al. Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systems. J Diabetes Sci Technol. 2015 Jan;9(1):24–33.
   PubMedGoogle Scholar
• Haidar A, Messier V, Legault L, et al. Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: an open-label, randomised, crossover, controlled trial. Diabetes Obes Metab. 2017 Jan 17;19:713–720.
   PubMed Web of Science ®Google Scholar
• Zisser H, Dassau E, Lee JJ, et al. Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion. J Diabetes Sci Technol. 2015 May;9(3):564–572.
   PubMedGoogle Scholar
• Weinzimer SA, Sherr JL, Cengiz E, et al. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care. 2012 Oct;35(10):1994–1999.
   PubMed Web of Science ®Google Scholar
• Sherr JL, Patel NS, Michaud CI, et al. Mitigating meal-related glycemic excursions in an insulin-sparing manner during closed-loop insulin delivery: the beneficial effects of adjunctive pramlintide and liraglutide. Diabetes Care. 2016 Jul;39(7):1127–1134.
   PubMed Web of Science ®Google Scholar
• Ilkowitz JT, Katikaneni R, Cantwell M, et al. Adjuvant liraglutide and insulin versus insulin monotherapy in the closed-loop system in type 1 diabetes: a randomized open-labeled crossover design trial. J Diabetes Sci Technol. 2016 Sep;10(5):1108–1114.
   PubMedGoogle Scholar